Diabetic Ketoacidosis

Diabetic Ketoacidosis (DKA) – High‑Yield Study Guide for Medical Students

Definition

Diabetic ketoacidosis (DKA) is an acute, life‑threatening complication of diabetes mellitus characterized by the triad of:

• Hyperglycemia (typically >250 mg/dL or >13.9 mmol/L)
• Metabolic acidosis with increased anion gap (arterial pH <7.30 and serum bicarbonate <18 mEq/L)
• Ketonemia and/or ketonuria due to increased production of ketone bodies

It results from absolute or relative insulin deficiency combined with an increase in counter‑regulatory hormones, leading to uncontrolled hyperglycemia, osmotic diuresis, dehydration, and ketoacidosis.

Epidemiology

DKA is more common in type 1 diabetes mellitus but can also occur in type 2 diabetes, especially in younger patients, those under stress, or in the presence of infection. It is a frequent cause of diabetes‑related hospitalization worldwide and a major contributor to diabetes‑related mortality, particularly in low‑resource settings where delayed diagnosis and suboptimal management are common.[1]

Typical epidemiologic features include:

• Common initial presentation of previously undiagnosed type 1 diabetes in children and adolescents
• Recurrent episodes in patients with poor glycemic control, psychosocial difficulties, or limited access to insulin
• Higher mortality in resource‑limited settings, often associated with delayed recognition and inadequate fluid/electrolyte therapy[1]

Pathophysiology

The pathophysiology of DKA revolves around insulin deficiency and excess counter‑regulatory hormones (glucagon, catecholamines, cortisol, growth hormone):

• Insulin deficiency impairs glucose uptake into insulin‑sensitive tissues (muscle and adipose) and reduces inhibition of hepatic gluconeogenesis and glycogenolysis.
• Increased counter‑regulatory hormones promote hepatic gluconeogenesis and glycogenolysis, further increasing plasma glucose.

This leads to several key processes:

• Hyperglycemia and osmotic diuresis: Excess glucose exceeds renal tubular reabsorptive capacity, causing glucosuria and osmotic diuresis with loss of water and electrolytes (Na⁺, K⁺, Cl⁻, Mg²⁺, PO₄³⁻). Resultant dehydration and volume depletion contribute to decreased GFR, which further worsens hyperglycemia.
• Lipolysis and ketogenesis: In the absence of insulin, hormone‑sensitive lipase in adipose tissue is activated, increasing lipolysis and release of free fatty acids. The liver converts free fatty acids to ketone bodies (acetoacetate, β‑hydroxybutyrate, and acetone). Ketone accumulation leads to high anion gap metabolic acidosis.
• Electrolyte shifts: Insulin deficiency and acidosis cause potassium to shift from intracellular to extracellular space, resulting in normal or high serum K⁺ despite total body K⁺ depletion. With therapy and correction of acidosis, K⁺ shifts back into cells, often unmasking profound hypokalemia.
• Inflammatory and oxidative stress: DKA is associated with systemic inflammatory responses that may contribute to endothelial dysfunction and organ injury.

Precipitating Factors

DKA typically occurs in the context of a physiological stressor or interruption of insulin therapy. Common precipitants include:

• Infection (most common): pneumonia, urinary tract infection, skin/soft tissue infections, sepsis
• Insulin omission or inadequate dosing: poor adherence, psychosocial issues, pump failure, financial barriers
• New‑onset diabetes: especially type 1, where DKA may be the first presentation
• Acute medical illness: myocardial infarction, stroke, pancreatitis, trauma, surgery
• Medications: glucocorticoids, sympathomimetics, atypical antipsychotics, SGLT2 inhibitors (can be associated with euglycemic DKA)
• Pregnancy: increased insulin resistance and reduced buffering reserve
• Substance use: alcohol, cocaine, or other illicit drugs

Clinical Presentation

The clinical features of DKA reflect the underlying hyperglycemia, dehydration, acidosis, and precipitating illness. Symptoms often evolve over hours to days.

Symptoms

• Polyuria and polydipsia: due to osmotic diuresis and dehydration
• Weight loss: subacute, especially in new‑onset type 1 diabetes
• Nausea, vomiting, and abdominal pain: abdominal pain can mimic an acute abdomen and is often proportional to the degree of acidosis
• Fatigue, weakness, malaise
• Shortness of breath: due to metabolic acidosis and compensatory hyperventilation
• Altered mental status: from mild confusion to lethargy, stupor, or coma in severe cases

Signs

• Dehydration: dry mucous membranes, poor skin turgor, tachycardia, hypotension
• Kussmaul respirations: deep, rapid breathing pattern as respiratory compensation for metabolic acidosis
• Fruity (acetone) odor on breath
• Signs of precipitating illness: fever, focal infection, chest pain, neurologic deficits, etc.
• Neurologic findings: from normal to reduced GCS, focal deficits are uncommon and should prompt evaluation for stroke or cerebral edema

Severity Classification

DKA is often stratified as mild, moderate, or severe based on laboratory and clinical criteria:

• Mild: pH 7.25–7.30, bicarbonate 15–18 mEq/L, alert
• Moderate: pH 7.00–7.24, bicarbonate 10–15 mEq/L, drowsy
• Severe: pH <7.00, bicarbonate <10 mEq/L, stupor/coma

These categories help guide monitoring intensity and setting (e.g., ICU vs general ward) but management principles remain similar.

Diagnosis

Diagnosis of DKA is based on a combination of clinical features and characteristic laboratory abnormalities. Key diagnostic features include:

• Hyperglycemia: plasma glucose typically >250 mg/dL (>13.9 mmol/L); note that in euglycemic DKA (often with SGLT2 inhibitors), glucose may be lower.
• Metabolic acidosis: venous or arterial pH <7.30, serum bicarbonate <18 mEq/L; anion gap >10–12.
• Ketonemia/ketonuria: positive serum ketones (β‑hydroxybutyrate preferred) or urine ketones (acetoacetate). Serum β‑hydroxybutyrate is more sensitive and specific.

Recommended Initial Laboratory Evaluation

• Plasma glucose
• Serum electrolytes (Na⁺, K⁺, Cl⁻, HCO₃⁻), BUN, creatinine
• Anion gap: Na⁺ − (Cl⁻ + HCO₃⁻)
• Serum β‑hydroxybutyrate (if available) and/or urine ketones
• Venous or arterial blood gas for pH and bicarbonate
• Serum osmolality (measured or calculated)
• Complete blood count
• Serum phosphate, magnesium, calcium (especially in moderate–severe DKA)
• ECG: to evaluate effects of potassium abnormalities and coexisting cardiac disease

Search for Precipitating Cause

Diagnostic work‑up should include evaluation for potential triggers:

• Chest X‑ray for pneumonia
• Urinalysis and urine culture for UTI
• Blood cultures if sepsis is suspected
• Cardiac enzymes and ECG for myocardial infarction
• Amylase/lipase and abdominal imaging if pancreatitis is suspected

Differential Diagnosis

Conditions that can mimic or coexist with DKA include:

• Hyperosmolar hyperglycemic state (HHS)
• Lactic acidosis
• Alcoholic ketoacidosis
• Starvation ketosis
• Salicylate toxicity
• Uremic acidosis

HHS generally presents with more severe hyperglycemia and hyperosmolality, minimal or absent ketosis, and no significant high‑anion‑gap acidosis.

Management – Overview and Principles

Effective DKA management relies on systematic correction of volume depletion, hyperglycemia, and electrolyte/acid–base abnormalities while identifying and treating the precipitating cause. Protocol‑driven care and team training have been shown to improve provider competence and patient outcomes.[2][1]

Core treatment pillars are:

• Fluid resuscitation
• Insulin therapy
• Potassium and electrolyte management
• Careful monitoring and adjustment of therapy
• Treatment of precipitating factors (e.g., antibiotics for infection)

Initial Assessment and Monitoring

Upon diagnosis, patients require rapid assessment and continuous monitoring:

• Baseline vitals: blood pressure, heart rate, respiratory rate, temperature, SpO₂, mental status
• Frequent capillary blood glucose (e.g., hourly until stable)
• Serial electrolytes, BUN/creatinine, and venous blood gases every 2–4 hours during acute management
• Strict intake/output charting and body weight measurement (if feasible)

Fluid Resuscitation

Goals: Restore intravascular volume, improve tissue perfusion, reduce counter‑regulatory hormones, and improve renal perfusion to enhance glucose and ketone clearance.

• Initial fluid choice: Isotonic saline (0.9% NaCl) is commonly used for the first phase of resuscitation.
• Typical regimen (adult) (adjust for comorbidities such as heart failure or renal impairment):
  • 1–1.5 L of 0.9% NaCl in the first hour (15–20 mL/kg), then adjust based on hemodynamics, urine output, and corrected sodium.
  • Subsequent fluids may be 0.45% NaCl if corrected serum sodium is normal or elevated.
• Add dextrose: When plasma glucose falls to ~200 mg/dL (11.1 mmol/L), switch to dextrose‑containing fluids (e.g., D5‑0.45% NaCl) to prevent hypoglycemia while continuing insulin to clear ketones.

Some centers use a two‑bag system (one bag with dextrose, one without) titrated dynamically to maintain appropriate glucose levels, which may facilitate fine‑tuning of fluid and dextrose delivery.[3]

Insulin Therapy

Goals: Suppress ketogenesis, reduce serum glucose gradually, and correct acidosis.

• Use regular insulin via continuous IV infusion in moderate to severe DKA (common regimen: 0.1 units/kg bolus followed by 0.1 units/kg/h infusion, or start infusion without bolus at 0.14 units/kg/h).
• Target a decrease in plasma glucose of approximately 50–75 mg/dL per hour to avoid rapid shifts in osmolality.
• Once glucose reaches ~200 mg/dL (11.1 mmol/L), reduce insulin infusion rate (e.g., to 0.02–0.05 units/kg/h) and add dextrose to IV fluids to continue ketone clearance while preventing hypoglycemia.

Emerging evidence suggests that early administration of subcutaneous basal insulin in combination with IV insulin infusion can reduce the time to resolution of DKA and minimize rebound hyperglycemia when transitioning off IV insulin.[4][5] Typical practice is to administer a basal insulin dose (e.g., glargine) 2–4 hours before discontinuing the insulin infusion, accommodating its onset of action.

Potassium and Electrolyte Management

Key concept: Despite often normal or elevated serum potassium at presentation, total body potassium is depleted. Insulin therapy and correction of acidosis will drive potassium back into cells, risking hypokalemia unless replacement is provided.

• Initial serum K⁺ <3.3 mEq/L: Hold insulin; start potassium replacement (e.g., 20–30 mEq/h) until K⁺ >3.3 mEq/L.
• Serum K⁺ 3.3–5.2 mEq/L: Start insulin and give potassium (e.g., 20–30 mEq K⁺ in each liter of IV fluid) to maintain K⁺ in the 4–5 mEq/L range.
• Serum K⁺ >5.2 mEq/L: Start insulin without initial potassium; monitor K⁺ every 2 hours and start replacement once K⁺ falls into normal range.

Other electrolytes:

• Sodium: Correct measured sodium for hyperglycemia. If corrected sodium is low, continue 0.9% NaCl; if normal/high, switch to 0.45% NaCl.
• Phosphate: Total body phosphate is depleted, but routine replacement is controversial. Replace if severe hypophosphatemia (<1.0 mg/dL), respiratory or cardiac dysfunction, or hemolysis is present.
• Magnesium: Monitor and replace as needed, particularly if arrhythmias or hypokalemia persist despite K⁺ replacement.

Bicarbonate Therapy

Bicarbonate therapy is not routinely indicated and may be harmful (e.g., risk of paradoxical CNS acidosis, hypokalemia). It is generally reserved for:

• Severe acidosis with arterial pH <6.9, where compromised cardiac contractility and vasodilation may impair hemodynamics.

In such cases, cautious administration of bicarbonate with careful monitoring of potassium and pH may be considered, following institutional protocols.

Transition to Subcutaneous Insulin

DKA is considered resolved when:

• Plasma glucose <200 mg/dL (11.1 mmol/L)
• Plus at least two of the following: serum bicarbonate ≥15 mEq/L, venous pH >7.3, anion gap ≤12 mEq/L

Once DKA has resolved and the patient can eat, transition from IV insulin to a subcutaneous regimen:

• Administer long‑acting basal insulin (e.g., glargine, detemir, NPH) 2–4 hours prior to discontinuation of the insulin infusion to prevent rebound hyperglycemia, as supported by evidence favoring early basal insulin in DKA management.[4]
• Design an appropriate basal–bolus regimen based on patient’s prior insulin needs or weight‑based dosing if newly diagnosed.

Special Populations and Considerations

• Children and adolescents: Higher risk of cerebral edema; avoid overly rapid correction of hyperglycemia and osmolar shifts. Fluid rates and insulin dosing should follow pediatric DKA guidelines.
• Elderly or comorbid patients: Adjust fluid and insulin dosing to account for cardiac and renal function; careful monitoring for fluid overload and ischemic events is essential.
• Pregnancy: Lower threshold for hospital admission and close maternal–fetal monitoring; DKA can occur at lower glucose levels.

Complications of DKA and Its Treatment

Potential complications include:

• Cerebral edema: Most common in children; presents with headache, altered mental status, seizures, bradycardia, and hypertension. It is rare but often fatal; suspected cases require urgent intervention.
• Hypoglycemia: From excessive insulin or delayed dextrose supplementation.
• Hypokalemia: Due to inadequate potassium replacement, can provoke arrhythmias.
• Acute kidney injury: From severe dehydration and hypotension.
• Thromboembolic events: Due to dehydration and hyperosmolarity.
• ARDS or pulmonary edema: Due to aggressive fluid administration in susceptible patients.

Prevention

Preventive strategies focus on patient education, sick‑day management, and health system support:

• Teach patients to monitor glucose and ketones during illness and to adjust insulin doses accordingly.
• Provide clear sick‑day plans (hydration, carbohydrate intake, when to seek medical attention).
• Ensure access to insulin and glucose monitoring supplies.
• Implement structured DKA education programs for clinicians to improve early detection and guideline‑based management, which have been shown to improve knowledge and confidence, especially in low‑resource settings.[1][2]

Key Clinical Pearls for Exams and Practice

• Diagnostic triad: Hyperglycemia, high‑anion‑gap metabolic acidosis, and ketonemia/ketonuria.
• Total body potassium is always low, even if serum K⁺ is normal or high at presentation. Anticipate the drop in K⁺ after insulin and correct acidosis with appropriate replacement.
• Insulin alone is not first: Begin with fluid resuscitation, then insulin once initial volume status is addressed and potassium is >3.3 mEq/L.
• Ketone clearance, not just glucose control, defines DKA resolution. Continue insulin infusion even after glucose normalizes, with dextrose‑containing fluids, until anion gap closes and bicarbonate improves.
• Beware euglycemic DKA (especially with SGLT2 inhibitors): Think of DKA in patients with metabolic acidosis and ketonemia even if glucose is <250 mg/dL.
• In children, cerebral edema is the feared complication; avoid rapid shifts in serum osmolality and monitor neurologic status frequently.
• Early basal insulin with IV insulin infusion helps smooth transition to subcutaneous therapy and reduce recurrence of hyperglycemia after stopping the drip.[4]
• Use standardized DKA protocols and simulation‑based training when available; these interventions enhance adherence to evidence‑based care and provider competence.[2]

Summary

Diabetic ketoacidosis is a common and potentially fatal complication of diabetes that demands rapid recognition and structured management. For medical students, mastery of the pathophysiology (insulin deficiency with excess counter‑regulatory hormones), the diagnostic triad (hyperglycemia, high‑anion‑gap metabolic acidosis, ketonemia), and the management priorities (fluids, insulin, potassium, and treatment of precipitating causes) is essential. Protocol‑driven care, early basal insulin use, and ongoing patient and provider education are key to reducing morbidity and mortality in DKA.[4][2]